First-line Afatinib for Non-Small Cell Lung Cancer in Real World Practice

被引：10

作者：

Kim, Y. ^{[1
]}

Sun, J. ^{[1
]}

Park, K. ^{[2
]}

Park, S. E. ^{[1
]}

Lee, S. ^{[3
]}

Ahn, M. ^{[1
]}

Ahn, J. S. ^{[3
]}

Lim, S. W. ^{[1
]}

Lee, H. ^{[1
]}

Cho, J. H. ^{[1
]}

Kim, H. K. ^{[4
]}

机构：

[1] Samsung Med Ctr, Dept Med, Div Hematol Oncol, Seoul, South Korea

[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hem Onc, Seoul, South Korea

[3] Samsung Med Ctr, Seoul, South Korea

[4] Samsung Med Ctr, Hematooncol, Seoul, South Korea

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期

关键词：

afatinib; EGFR; non-small cell lung cancer;

D O I：

10.1016/j.jtho.2017.09.1464

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.01-023

引用

页码：S2209 / S2209

页数：1

共 50 条

[1] Real-world experience with afatinib as first-line treatment in advanced non-small cell lung cancer in a university hospital
Jang, Taewon
Kim, Jaehoon
CANCER RESEARCH, 2019, 79 (13)
[2] A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Yoon, S. H.
Kim, Y. S.
Chung, J. H.
Seol, H. Y.
Kim, M. H.
ANNALS OF ONCOLOGY, 2019, 30
[3] Real-World Experience of First-Line Afatinib Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer
Liam, C.
Ho, G.
Chai, C.
Alip, A. Bt
Pang, Y.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S998 - S999
[4] Efficacy and prognostic factors of first-line afatinib treatment for the EGFR-mutated non-small cell lung cancer in the real world
Chiu, Tzu Hsuan
Huang, Chi-Hsien
Kuo, Chih-Hsi Scott
EUROPEAN RESPIRATORY JOURNAL, 2020, 56
[5] Overall Survival of Advanced Non-Small Cell Lung Cancer Treated with First-Line Afatinib: A Multicenter Real-World Study in Vietnam
Pham, C. T. M.
Truong, M. C.
Do, T. A.
Pham, P. C.
Nguyen, H. T. T.
Nguyen, K. T.
Hoang, T. T. A.
Le, A. T.
Vuong, H. D. T.
Nguyen, T. D. N.
Dang, K. V.
Nguyen, O. T.
Luan, P. V.
Nguyen, H. M.
Vo, T. T. H.
Do, K. H.
Vu, T. H.
Nguyen, H. T. T.
Pham, T. V.
Trinh, H. L.
Nguyen, G. H.
Nguyen, P. T. B.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S630 - S631
[6] Real World Study of Afatinib in First-Line or Re-Challenge Setting for Patients with EGFR Mutant Non-Small Cell Lung Cancer
Tanaka, H.
Taima, K.
Itoga, M.
Ishioka, Y.
Baba, K.
Shiratori, T.
Tanaka, Y.
Nakagawa, H.
Morimoto, T.
Hasegawa, Y.
Yasugahira, H.
Okudera, K.
Takanashi, S.
Tasaka, S.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S984 - S984
[7] Real-World Multicenter Experience of First-line Afatinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer
Liam, C. K.
Chai, C.
Ho, G.
Alip, A.
Wahid, M. I. A.
Abdullah, M. M.
Foo, Y. C.
How, S. H.
Zaatar, A.
Lam, K. S.
Leong, K. W.
Low, J. S. H.
Yusof, M. Md
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S848 - S848
[8] Real world study of afatinib in first-line or re-challenge setting for patients with EGFR mutant non-small cell lung cancer
Tanaka, Hisashi
Taima, Kageaki
Itoga, Masamichi
Ishioka, Yoshiko
Baba, Keisuke
Shiratori, Toshihiro
Tanaka, Yoshihito
Nakagawa, Hideyuki
Tsuchiya, Junichiro
Hasegawa, Yukihiro
Sakamoto, Hiroaki
Yasugahira, Hideo
Okudera, Koichi
Takanashi, Shingo
Tasaka, Sadatomo
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[9] Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience
Ricciuti, Biagio
Baglivo, Sara
De Giglio, Andrea
Chiari, Rita
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2018, 12
[10] Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice
Brueckl, Wolfgang M.
Reck, Martin
Griesinger, Frank
Schaefer, Harald
Kortsik, Cornelius
Gaska, Tobias
Rawluk, Justyna
Krueger, Stefan
Kokowski, Konrad
Budweiser, Stephan
Ficker, Joachim H.
Hoffmann, Christopher
Schueler, Andrea
Laack, Eckart
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13

← 1 2 3 4 5 →